Mode
Text Size
Log in / Sign up

Immunosenescence drives pro-inflammatory immune shifts and impaired bone remodeling in osteoporosisAging immune systems may drive bone loss in osteoporosis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that immunosenescence promotes pro-inflammatory shifts and RANKL expression, potentially impacting bone remodeling.

This systematic review explores the role of immunosenescence in the pathogenesis of osteoporosis and its impact on bone remodeling. The review synthesizes data regarding various immune cell populations, highlighting how aging affects the bone microenvironment. Specifically, the review notes that immunosenescence is associated with enhanced M1 proinflammatory polarization in macrophages, increased oxidative burst and delayed apoptosis in neutrophils, and a loss of cytotoxic capacity in natural killer cells.

Furthermore, the review identifies an expansion of T helper 17 cells and a functional decline in regulatory T cells. These immune shifts correlate with a shift in B cells toward RANKL expression and an elevated RANKL/OPG ratio. These changes are associated with promoted osteoclastogenesis and suppressed osteoblast function.

While the synthesis suggests a potential for immune-centered prevention and treatment of osteoporosis and fracture complications in the elderly, the authors note that direct human causal evidence remains limited for several immune cell populations. Clinical application of these findings is currently limited by the lack of direct human evidence for specific cellular mechanisms.

How this fits prior evidence

This systematic review addresses a gap in understanding the immunological mechanisms of bone loss. While prior coverage noted that microbiota-directed interventions show inconsistent clinical efficacy for reducing fracture risk in osteoporosis, this review focuses on the role of immunosenescence and its impact on bone remodeling. It provides a different mechanistic perspective on how the aging immune system contributes to the progression of osteoporosis.

As we age, our immune systems undergo a process called immunosenescence. This is essentially the gradual aging of immune cells. New research highlights how these changes directly impact bone health, potentially contributing to the development of osteoporosis and making it harder for the body to repair fractures.

The review found that aging leads to specific shifts in immune cells. For example, certain cells that normally help manage inflammation become overactive, while others that protect the body lose their ability to function. These changes create a lopsided environment where the body promotes the breakdown of bone tissue while suppressing the cells that build it. This imbalance is linked to an increase in a specific protein ratio that signals the body to break down bone.

While these findings offer a new way to think about osteoporosis, it is important to note that direct evidence in humans for several specific immune cell types is still limited. However, understanding these links could help doctors develop new ways to protect bone health in older adults by targeting the immune system.

What this means for you:
Aging immune cells can trigger bone breakdown, offering a new path for treating osteoporosis in older adults.

Common questions

How does an aging immune system affect bone health?

As the immune system ages, it undergoes changes that can lead to more inflammation and less effective cell function. These changes can promote the breakdown of bone tissue and suppress the cells responsible for building bone, which contributes to the development of osteoporosis.

What specific changes occur in the body's cells?

The review found that certain cells, like macrophages and neutrophils, show increased inflammation. Other cells, like natural killer cells and regulatory T cells, show a decline in function. These shifts can lead to an increased RANKL to OPG ratio, which signals the body to break down bone.

Is there enough evidence to treat osteoporosis this way?

While the link between immune cells and bone loss is clear in research, direct human causal evidence is still limited for several specific immune cell populations. You should talk to your doctor about how these findings might apply to your specific health needs.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
With advancing age, the immune system undergoes progressive remodeling termed immunosenescence, which is intimately linked to skeletal homeostasis through the shared bone marrow microenvironment. This review systematically examines how senescent innate and adaptive immune cells disrupt bone remodeling by altering the cytokine milieu and releasing senescence-associated secretory phenotype (SASP) factors. Aged macrophages exhibit enhanced M1 proinflammatory polarization, while neutrophils display increased oxidative burst and delayed apoptosis. Natural killer cells lose cytotoxic capacity, and dendritic cells show impaired antigen presentation yet elevated basal inflammation. Within the adaptive compartment, T helper 17 (Th17) cells expand, regulatory T cells (Tregs) undergo functional decline and lineage instability, and B cells shift from osteoprotegerin (OPG) production toward receptor activator of nuclear factor kappa B ligand (RANKL) expression. These changes collectively elevate the RANKL/OPG ratio, promote osteoclastogenesis, and suppress osteoblast function. Systemic factors including estrogen deficiency and gut dysbiosis further amplify this immune-driven bone loss. Emerging therapeutic strategies range from conventional anti-resorptive agents to senolytics and immune modulators that restore marrow homeostasis. Understanding immunosenescence as an important contributor to skeletal aging provides a conceptual framework for immune-centered prevention and treatment of osteoporosis and fracture complications in the elderly, while recognizing that direct human causal evidence remains limited for several immune cell populations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.